ImmunityBio Past Earnings Performance
Past criteria checks 0/6
ImmunityBio's earnings have been declining at an average annual rate of -26.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 9.7% per year.
Key information
-26.6%
Earnings growth rate
-16.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 9.7% |
| Return on equity | n/a |
| Net Margin | -45,691.7% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How ImmunityBio makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 1 | -598 | 161 | 200 |
| 31 Mar 24 | 0 | -601 | 144 | 201 |
| 31 Dec 23 | 1 | -583 | 135 | 227 |
| 30 Sep 23 | 1 | -458 | 123 | 238 |
| 30 Jun 23 | 1 | -473 | 117 | 256 |
| 31 Mar 23 | 1 | -430 | 101 | 266 |
| 31 Dec 22 | 0 | -417 | 109 | 242 |
| 30 Sep 22 | 1 | -400 | 93 | 241 |
| 30 Jun 22 | 1 | -376 | 103 | 218 |
| 31 Mar 22 | 1 | -370 | 119 | 209 |
| 31 Dec 21 | 1 | -347 | 127 | 192 |
| 30 Sep 21 | 0 | -323 | 124 | 186 |
| 30 Jun 21 | 0 | -301 | 112 | 174 |
| 31 Mar 21 | 1 | -264 | 97 | 154 |
| 31 Dec 20 | 1 | -222 | 61 | 140 |
| 30 Sep 20 | 2 | -176 | 56 | 110 |
| 31 Dec 19 | 2 | -158 | 46 | 112 |
| 31 Dec 18 | 3 | -84 | 29 | 47 |
Quality Earnings: 26CA is currently unprofitable.
Growing Profit Margin: 26CA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 26CA is unprofitable, and losses have increased over the past 5 years at a rate of 26.6% per year.
Accelerating Growth: Unable to compare 26CA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 26CA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.6%).
Return on Equity
High ROE: 26CA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.